Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Affimed N.V.
Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.
- Large Molecule
- Other Names / Subsidiaries
- AbCheck s.r.o.
- Affimed Spinco Inc.
- Affimed Therapeutics AG
- Amphivena Therapeutics Inc.